COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析

doi:10.11904/j.issn.1002-3070.2019.01.009

摘要/Abstract

摘要： 目的探讨COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性。方法选取洪湖市人民医院膀胱癌患者144例,实时荧光逆转录法及免疫组化法测定膀胱癌组织及正常膀胱组织中COL5A2 mRNA及蛋白的表达水平,分析其与临床病理参数和预后的关系。结果膀胱癌组COL5A2 mRNA表达水平高于癌旁组(P＜0.05);膀胱癌组COL5A2阳性率高于癌旁组(P＜0.05);COL5A2蛋白表达与年龄无关(P＞0.05);与TMN分期、病理学分级、肿瘤最大径、浸润深度、淋巴结转移、淋巴血管间隙浸润、复发有关(P＜0.05),且TMN分期越高、病理学分期越高、肿瘤最大径≥5cm、浸润深度越深、有淋巴结转移、有淋巴血管间隙浸润、有复发,COL5A2蛋白阳性表达率越高;COL5A2阴性组3年生存率及生存期均明显高于COL5A2阳性组(P＜0.05)。结论 COL5A2在膀胱癌组织中表达量增加,其在膀胱癌的发生发展过程中起促进作用;COL5A2低表达的膀胱癌患者能获得较好的预后。

关键词: COL5A2, 膀胱癌, 临床病理特征, 预后

Abstract: Objective The aim of this study was to investigate the expression of COL5A2 in bladder cancer tissues,and its correlation with clinicopathological features and prognosis.Methods A total of 144 patients with bladder cancer were enrolled in this study.Real-time fluorescence reverse transcription and immunohistochemistry were used to detect the expression of COL5A2 at levels of mRNA and protein in bladder cancer tissues and normal bladder tissues.The relationship between COL5A2 expression and clinicopathological features and prognosis was analyzed.Results The expression of COL5A2 mRNA in the bladder cancer group was higher than that in the paracancerous group(P＜0.05).The positive rate of COL5A2 in the bladder cancer group was higher than that in the normal bladder tissues(P＜0.05).The expression of COL5A2 protein was not correlated with age(P＞0.05),positively associated with the TMN stage,pathological grade,tumor maximum diameter(≥5cm),depth of invasion,lymph node metastasis,lymphatic vascular infiltration,and recurrence;the difference was statistically significant(P＜0.05).The 3-year survival rate and survival time in the COL5A2 negative group were significantly higher than those in the COL5A2 positive group(P＜0.05).The higher TMN stage,the higher pathological stage,the maximum diameter of the tumor(≥5cm),the deeper infiltration depth,lymph node metastasis,lymphatic vascular infiltration,recurrence,the higher positive expression rate of COL5A2 protein.Conclusion COL5A2 is highly expressed in the bladder cancer tissues,which promotes the development of bladder cancer.Bladder cancer patients with low expression of COL5A2 can obtain a good prognosis.

Key words: COL5A2, Bladder cancer, Clinicopathological features, Prognosis

杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.

YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.

参考文献

1 王华,李方印,章伟.非肌层浸润性膀胱癌治疗现状及进展[J].肿瘤学杂志,2017,23(7):578-586.
2 黄金明.经尿道膀胱肿瘤切除术联合髂内动脉栓塞化疗治疗高龄高危浸润性膀胱癌的临床效果[J].中国内镜杂志,2017,23(3):99-103.
3 刘清源,段小雨,王灵点,等.非肌层浸润型膀胱癌术后膀胱热灌注化疗与常温灌注化疗的疗效对比分析[J].中华实用诊断与治疗杂志,2017,31(2):174-175.
4 Sanli O,Dobruch J,Knowles MA,et al.Bladder cancer[J].Nat Rev Dis Primers,2017,3(3):17022-17024.
5 Antoni S,Ferlay J,Soerjomataram I,et al.Bladder cancer incidence and mortality:A global overview and recent trends[J].Eur Urol,2017,71(1):96-98.
6 Akbani R,Al-Ahmadie H,Albert M,et al.Comprehensive molecular characterization of muscle-invasive bladder cancer[J].Cell,2017,171(3):540-556.
7 Bellmunt J,Powles T,Vogelzang NJ.A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer:The future is now[J].Cancer Treat Rev,2017,54(3):58-60.
8 Zeng XT,Liu XP,Liu TZ,et al.The clinical significance of COL5A2 in patients with bladder cancer:A retrospective analysis of bladder cancer gene expression data[J].Medicine,2018,97(10):91-93.
9 Park AC,Phan N,Massoudi D,et al.Deficits in Col5a2 Expression result in novel skin and adipose abnormalities and predisposition to aortic aneurysms and dissections[J].Am J Pathol,2017,187(10):56-58.
10 Park AC,Phillips CL,Pfeiffer FM,et al.Homozygosity and heterozygosity for null col5a2 alleles produce embryonic lethality and a novel classic ehlers-danlos syndrome-related Phenotype[J].Am J Pathol,2015,185(7):2000-2011.
11 Spiess PE,Agarwal N,Bangs R,et al.Bladder cancer,version 5.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(10):1240-1242.
12 Watanabe M,Nakagawa R,Naruto T,et al.A novel missense mutation of COL5A2in a patient with ehlers-danlos syndrome[J].Human Genome Variation,2016,3(3):16030-16031.
13 郭鹏飞,贺平安.乳腺癌癌症干细胞的特异基因识别[J].浙江理工大学学报:自然科学版,2017,37(3):451-460.
14 Jeanne M,Gould DB.Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations[J].Matrix Biol,2016,5(3):57-58.
15 Jingsong H,Hong G,Yang J,et al.siRNA-mediated suppression of collagen type iv alpha 2(COL4A2)mRNA inhibits triple-negative breast cancer cell proliferation and migration[J].Oncotarget,2016,8(2):56-58.
16 Miyake M,Hori S,Morizawa Y,et al.Collagen type IV alpha 1(COL4A1)and collagen type XIII alpha 1(COL13A1)produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder:[J].Oncotarget,2017,8(22):36099-36114.
17 Cong G,Zhao J,Zhou M,et al.Relationship of gene polymorphism of collagen typeⅠ alpha 2 chains and dental fluorosis in children in Qinghai Tibet Plateau[J].Jiangsu Medical Journal,2016,6(2):43-45.
18 Fischer H,Stenling R,Rubio C,et al.Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2[J].Carcinogenesis,2001,22(6):875-878.
19 Gistelinck C,Gioia R,Gagliardi A,et al.Zebrafish collagen type I:molecular and biochemical characterization of the major structural protein in bone and skin[J].Sci Rep,2016,6(3):21540-21542.
20 Qi G,Liu Q,Xin H,et al.Collagen type I alpha 2(COL1A2)polymorphism contributes to intracranial aneurysm susceptibility:a meta-analysis[J].Med Sci Monit,2017,23(3):3240-3246.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[10]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[11]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[12]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[13]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[14]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[15]	杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.